NCT03887871View on ClinicalTrials.gov

"Study to Evaluate the Bioequivalence of Astellas Phama Korea Inc. Harnal-D in Healthy Volunteers After Meal"

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 11, 2019

Primary Completion Date

March 22, 2019

Study Completion Date

April 23, 2019

Conditions
Benign Prostatic Hyperplasia
Interventions
DRUG

Harnal-D Tab.

Harnal-D Tab. 1T single oral administration after meal

DRUG

Chong Kun Dang Tamsulosin HCl Tab.

Chong Kun Dang Tamsulosin HCl Tab. 1T single oral administration after meal

Trial Locations (1)

Unknown

Bestian Hospital, Osŏng

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY

NCT03887871 - "Study to Evaluate the Bioequivalence of Astellas Phama Korea Inc. Harnal-D in Healthy Volunteers After Meal" | Biotech Hunter | Biotech Hunter